Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · PubMed · 2009 · 45.1K citations · Full text

Nursing, Biostatistics, Evidence-based Practice +10

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al. · Journal of Clinical Epidemiology · 2009 · 19.9K citations · Full text

Public Health, Biostatistics, Evidence-based Practice +11

Cancer statistics, 2018

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +16